Back to search

Article

Effects of anlotinib combined with second-line chemotherapy on the levels of immune cells and inflammatory factors and the curative effects in patients with advanced non-small cell lung cancer

2022-12-08

Abstract excerpt

<h4>Objective: </h4> To investigate the effects of anlotinib combined with second-line chemotherapy on the levels of immune cells and inflammatory factors and the curative effects in patients with advanced non-small cell lung cancer. <h4>Methods:</h4> A total of 106 patients with advanced non-small cell lung cancer were selected from November 2020 to March 2022 for clinical and hospital treatment as the research s...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
680d119d-7125-5838-b3d2-6c9b345c219d
DOI
10.22541/au.167051195.58320267/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Effects of anlotinib combined with second-line chemotherapy on the levels of immune cells and inflammatory factors and the curative effects in patients with advanced non-small cell lung cancerDOI 10.22541/au.167051195.58320267/v1
Effect of PD-1 inhibitor combined with chemotherapy on cytokines and immune cell function in patients with advanced lung cancerSemantic proximity
Characteristics and Hematological Indicators Predictors of Immunotherapy Response in Advanced Non-Small Cell Lung CancerSemantic proximity
A systematic review and meta-analysis on effectiveness and safety of traditional Chinese medicine combined with EGFR-TKIs in treating advanced non-small cell lung cancerSemantic proximity
Comparative Safety of Immune Checkpoint Inhibitors and Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-AnalysisSemantic proximity
Real-World Outcomes and Clinical Heterogeneity of First-Line Immunochemotherapy in Extensive-Stage Small-Cell Lung CancerSemantic proximity
A retrospective study of tislelizumab combined with chemotherapy for downstaging and conversion therapy in patients with locally advanced lung cancerSemantic proximity
Real-world Data Analysis of Immunotherapy in Advanced Lung CancerSemantic proximity
Pre-treatment Neutrophil-to-Lymphocyte Ratio significantly affects progression free survival in positive EGFR mutation advanced lung adenocarcinoma with EGFR-TKI treatment in Bali, Indonesia.Semantic proximity
[Efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy as first-line treatment for epidermal growth factor receptor-mutant advanced non-small cell lung cancer].Semantic proximity
Predictive value of the biomarker of peripheral blood of NSCLC patients responding to anti-PD-1 treatmentSemantic proximity
Efficacy and Safety of Immuno-based Therapy Versus Standard of Care in Extensive-stage Small-Cell Lung Cancer: An Updated Meta-analysis of Randomized Clinical TrialsSemantic proximity
Efficacy and safety of immune checkpoint inhibitors versus chemotherapy in advanced non-small cell lung cancer: A systematic review of randomized controlled trialsSemantic proximity
Select a neighboring publication to make it the new centre.